Uterine Fibroids – Epidemiology – Mature Markets
We reviewed the published literature, including online registries and surveys, using a systematic search with a defined date range, for the most representative epidemiological data on uterine fibroids.
We summarize the results of our review for the epidemiological estimates of prevalence that are used directly in our forecast model in the “Studies Included in the Analysis” table. How we used these estimates and to which countries they were applied are discussed in the text and summarized in the “Sources Used” table(s). We report the most relevant sources excluded and the reason for excluding them in the “Studies Excluded from the Analysis” table.
Table of contents
- Uterine Fibroids - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Overview
- Total Prevalence of Uterine Fibroids per 100 Women Aged 20-54 in 2020 and 2040
- Total Prevalence of Uterine Fibroids per 100 Women Aged 20-54 in 2020 and 2040
- Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Uterine Fibroids over the Next 20 Years
- Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Uterine Fibroids over the Next 20 Years
- Analysis of Total Prevalent Cases of Uterine Fibroids by Diagnosed and Drug-Treated Status
- Analysis of Total Prevalent Cases of Uterine Fibroids by Diagnosed and Drug-Treated Status
- Key Findings
- Epidemiology Data
- Methods
- Reference Materials
- Introduction
Julie Davis, M.P.H., Senior Epidemiologist, Epidemiology. Before joining Clarivate, Ms. Davis was a research assistant at Tufts Medical Center, where she studied accelerated osteoarthritis and other rheumatic diseases. She also has experience working with zoonotic disease transmission in Ethiopia and excess mortality in Puerto Rico stemming from Hurricane Maria. She was part of the Health Emergencies team at the Pan American Health Organization, working on disaster preparedness and disease risk assessments. Ms. Davis holds a master’s degree in global health epidemiology and disease control from George Washington University and a B.S. in health sciences from James Madison University.
Oliver Blandy, M.Sc., is a senior epidemiologist at Clarivate. Previously, Oliver worked as a research assistant for Imperial College London, where he was the lead for several studies within an NIRH-funded research group investigating healthcare-associated infections and antimicrobial resistance. He holds an M.Sc. from the University of Bristol, where he specialized in nutrition, physical activity, and public health. He also holds a B.Sc. in chemistry and a postgraduate certificate in education, both from the University of Bristol.